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Table 1
Characteristics N¼20
Median age; years (range) 59 (26-72)
Male (%) 13 (65%)
Diagnosis, no. (%)
Acute Myeloid Leukemia 4 (20%)
Non-Hodgkin Lymphoma 11 (55%)
Chronic Leukemia (CLL or CML) 4 (20%)
Hemophagocytic syndrome 1 (5%)
Disease risk, no. (%)
High risk 5
Intermediate risk 10
Low risk 4
Prior autografting, no. (%)
Yes 1 (5%)
No 19 (95%)
Donors, no. (%)
Related 5 (25%)
Unrelated 15 (75%)
Sex mismatch, no (%)
M to M 9 (45%)
M to F 3 (15%)
F to M 4 (20%)
F to F 4 (20%)
Degree of HLA match, no. (%)
10/10 19 (95%)
9/10 1 (5%)
Median KPS; (range) 80 (70-100)
Median HCT-CI; (range) 1 (0-5)
Median CD34 cell dosey (106 cells/kg recipient body weight),
(range)
5.7 (1.5-11.3)
Abstracts / Biol Blood Marrow Transplant 19 (2013) S313eS341 S339summarizes cohort data. Elevated Kyn/Trp ratio correlated
with GVHD compared to non-GVHD cohort (p ¼ 0.027).
LikewiseAUCKyn/Trp ratio correlatedwithGVHD (p¼0.007).
Mortality rate was 50% at a median of 98 days post-HSCT.
Conclusions: IDO activity is associated with acute GVHD and
may be a useful biomarker to assist with GVHD diagnosis.
Future validation studies are needed to conﬁrm these ﬁnd-
ings, which should be considered in clinical trials that target
IDO induction for prevention or treatment of GVHD
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We have used home care as an option to hospital-care during
the pancytopenic phase after hematopoietic allogeneic stem
cell transplantation (HSCT) for 15 years at Karolinska
University Hospital . This is now an opportunity for children
as well as for adults. A nurse from the unit visited and
checked the patient regularly.
After treating 146 patients at home we compared them to
hospital controls matched for sex, age, diagnosis, stage of
disease, type of donor, source of stem cells and conditioning.
Oral intake was intensiﬁed from September 2006 and
improved (P ¼ .002). More calories per day was associated
with less GVHD in an univariate analysis (P ¼ .02). In multi-
variate analysis grades 0eI GVHD was associated with home
care (HR¼2.46, P ¼ .02) and with days spent at home
(HR¼0.92, P¼ .005), but notwith oral nutrition (HR¼0.98, P¼
.13). Transplant-related mortality, chronic GVHD and relapse
were similar in the groups. Five-year survival was 61% in the
home care group as compared to 49% in the controls (P¼ .07).
When we analyzed outcome of HSCT for the past two
decades, we found that low transplant-related mortality
(TRM) was associated with age (P < .001), acute leukemia (P
¼ .002), HLA-identical related donor (P < .001), reduced
intensity conditioning (P ¼ .007) and home care (P ¼ .02).
Wecollectedall in-andoutpatient costsduring twoyearsatour
unit. Costsduring the initial transplantperioduntil day76were
signiﬁcantly lowerwith home care inmultivariate analysis (RH
0.8,P ¼ .035). Increased costs were associated with a second
transplant, T-cell depletion, adults, G-CSF and complications.
To show Quality of life we used The Sympathy- Acceptance-
Understanding-Competence-questionnaire (SAUC) instrument
developed from the SAUC-model. This study aim to describe
patients’ experiences of care and support from healthcare staff
while treated in hospital or at home during the early post
transplantationphase afterHSCT. The studyshowedhomecare
to beas satisfactoryashospital-care. Also24 relatives staying at
home together with the patients gave their opinion regarding
quality of life. Eleven questions were asked in a survey with
a scale from 1-5 where 1 was very satisfactory and 5 was the
opposite. 21 rated 1-2 very satisfactory and three rated 2-3.
Conclusion: Home care is safe and cheaper than hospital
care. Home care and many days spent at home were corre-
lated with a low risk of acute GVHD. Home care was also
associated with a lower TRM and a trend for better survival.461
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Non-myeloablative (NMA) conditioning with total lymphoid
irradiation and antithymocyte globulin (TLI/ATG) has been
shown to protect against acute graft-versus-host disease
(GVHD), while preserving graft-versus-malignancy effects.
Reported here is our institutional experience with allogeneic
hematopoietic cell transplantation (allo-HCT) following TLI/
ATG conditioning. Criteria used to select TLI/ATG condi-
tioning included; age 65 and/or HCT-CI of >3. Patients
received ATG (1.5 mg/kg/day) from day -11 through -7 and
a total dose of 8Gy of TLI administered from day -11 through
-1 followed by cell infusion of day 0. GVHD prophylaxis
consisted of combination of either cyclosporine/mycophe-
nolate mofetil (MMF) or tacrolimus/MMF in those under-
going a matched sibling or unrelated donor allo-HCT,
respectively. Table 1 summarizes the baseline patient char-
acteristics (n¼20). The median follow up for surviving
patients is 723 days (range 180-1364 days). All patients
engrafted, except onewho experienced primary engraftment
failure. The median time to neutrophil engraftment was 16
days (range 9-23 days) and platelet engraftment was 10 days
(range 6-24 days). Median donor chimerism on days +30,
+100 and +365 was 93% (range 60-100%), 95% (range 54-
